Lysyl oxidases directly control cell surface abundance of platelet-derived growth factor receptors and signaling in osteoblasts
December 6, 2025
A phase 1/2a trial of amsulostat, a novel pan-lysyl oxidase inhibitor, in patients with advanced myelofibrosis as an add-on to ruxolitinib treatment for up to 52 weeks
